Regenerative Medicine

Multiple animal models are used in regenerative medicine preclinical product development including:

• Gene knockout/knockin/trapped
• Transgenic rodents
• Chemically-Induced Point Mutation rodents
• Stress-induced models
• Drug-Induced models
• Wound/Laceration Models
• Metabolically-induced models (Diet-induced, Metabolic disorder, micronutrient deficient)
• And more…

We conduct translational animal studies (in vivo and in vitro) collecting detailed, comprehensive results with rapid turnaround.

AniLocus provides preclinical CRO solutions for the following therapeutic areas in regenerative medicine:

Neurodegenerative Disorders
Alzheimer’s Disease
Amyotrophic Lateral Sclerosis (ALS)
Anxiety
Attention Deficit Hyperactivity Disorder
Autism Spectrum Disorders
Cerebral Stroke/Ischemia
Concussions
Depression
Epilepsy
Huntington’s Disease
Multiple sclerosis (MS)
Olfactory Degeneration/Dysfunction
Parkinson’s Disease
Schizophrenia
Traumatic Brain Injury

Degenerative Joint, Bone and Spine Disease
Diffuse Idiopathic Skeletal Hyperostosis (DISH)
Disc Degeneration
Osteoarthritis
Osteoporosis
Spine Curvatures (Kyphosis, Lordosis, and Scoliosis)
Spondylitis
Stenosis

Degenerative Eye Disorders
Age-related macular degeneration (AMD)
Cataract
Diabetic Retinopathy
Glaucoma

Degenerative Autoimmune Disorders
Autoimmune Motor Neuron Disease (EAMD)
Fibromyalgia/Chronic Fatigue Syndrome (CFS)
Psoriasis/Psoriatic Arthritis
Rheumatoid Arthritis
Systemic Lupus Erythematosus (SLE)
Tourette syndrome

Injury, Wound Healing, and Trauma
Amputation
Chemical Burns & Injury
Chronic Wounds
Necrotizing Tissue
Revascularization
Soft Tissue Injuries
Surgical Wound Healing
Thermal Burns
Tissue Grafts
Ulcerations
Weapon/Battlefield Trauma
Wound Dressings

Drug modalities are different types of therapeutic agents. Each drug is a customizable tool designed for therapeutic intervention. The question is…does your product work and is it safe?

At AniLocus, we conduct relevant preclinical studies to assess any drug modality:

• Antibodies (nanobodies, monoclonal)
• Gene therapy (CRISPR, TALEN)
• Viral therapy (adenovirus-AAV, lentivirus)
• Oligo- and polypeptides (e.g., stapled and modified peptides)
• Oligo- and polynucleotides (e.g., siRNAs, mRNAs, aptamers)
• Polyglycosides
• Macrocyclic molecules
• Drug conjugates (e.g., antibody–drug conjugates, drug–drug conjugates, fluorescence-labeled drugs)
• Targeted protein degraders (e.g., proteolysis-targeting chimeras (PROTACs) and molecular glues) that induce a chemical knockdown of proteins
• Cellular therapies (stem cells, allogenic, autologous)

Using animal and human cells and tissue we can perform multiple interrogative assays depending on therapeutic area and sample type:

• DNA: Extraction, PCR, ddPCR, qPCR, sequencing, genotyping
• RNA: Gene expression profiling, RT-PCR, miRNA, Next-generation sequencing (Nanostring, Illumina), spatial transcriptomics, In situ hybridization (ISH), Multiplex ISH
• Protein: Immunoassays (ELISA, EIA, Luminex), proteomics, ligand binding assays, protein expression, immunohistochemistry (IHC), immunocytochemistry (ICC), and  immunofluorescence (IF)
• And more!

1. GBD 2019 Dementia Forecasting Collaborators (2022). Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. The Lancet. Public health, 7(2), e105–e125..
2. de Haan P, Klein HC, ‘t Hart BA. Autoimmune Aspects of Neurodegenerative and Psychiatric Diseases: A Template for Innovative Therapy. Front Psychiatry. 2017 Apr 4;8:46. doi: 10.3389/fpsyt.2017.00046. PMID: 28421005; PMCID: PMC5378775.
3. World Health Organization. Schizophrenia. Newsroom Fact Sheets. Published: 10 January 2022. < https://www.who.int/news-room/fact-sheets/detail/schizophrenia >.
4. International Osteoporosis Foundation. EPIDEMIOLOGY OF OSTEOPOROSIS AND FRAGILITY FRACTURES. Facts & Statistics. Accessed: 15 Oct 2022. < https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures >.
5. GBD 2016 Neurology Collaborators (2019). Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. Neurology, 18(5), 459–480. < https://doi.org/10.1016/S1474-4422(18)30499-X >.
6. Park, Y. J., Niizuma, K., Mokin, M., Dezawa, M., & Borlongan, C. V. (2020). Cell-Based Therapy for Stroke: Musing With Muse Cells. Stroke, 51(9), 2854–2862. < https://doi.org/10.1161/STROKEAHA.120.030618. >